Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司股东减持计划公告
Regulatory Filings
2026-05-07 Chinese
2025年度独立董事述职报告（薛军福）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from Chengdu Lead Drug Development Co., Ltd. It details the independent director's background, attendance at board and committee meetings, participation in governance and audit activities, and overall evaluation of their duties during the year. The content focuses on the director's duties, governance, and oversight rather than financial results or audit opinions. It is a specialized governance-related report by an independent director, not a full annual report, audit report, or regulatory filing. This fits best under Board/Management Information (MANG) as it relates to board member duties and governance activities. The document length (4824 characters) and detailed content support this classification with high confidence.
2026-04-28 Chinese
成都先导药物开发股份有限公司2025年度可持续发展报告摘要
Environmental & Social Information Classification · 95% confidence The document is titled '2025年度可持续发展报告摘要' which translates to '2025 Sustainable Development Report Summary'. It references sustainability topics such as ESG (Environmental, Social, and Governance) issues, governance, environmental management, social responsibility, and related frameworks and guidelines. The document is a summary of a sustainability report, focusing on the company's performance and strategy regarding environmental and social factors. It does not contain financial statements or earnings data, nor is it an announcement of a financial report. The content aligns with the definition of an Environmental & Social Information report (ESG report). The document length is 3660 characters, which is relatively short but the content is substantive on sustainability topics, not a mere announcement. Therefore, the appropriate classification is Environmental & Social Information (SR).
2026-04-28 Chinese
德勤华永会计师事务所(特殊普通合伙)关于成都先导药物开发股份有限公司控股股东、实际控制人及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation regarding the use of funds by the controlling shareholders, actual controllers, and other related parties of Chengdu Lead Drug Development Co., Ltd. for the fiscal year ending December 31, 2025. It includes a summary table of non-operating fund occupation and other related party fund transactions, audited by Deloitte, with references to the audit report issued on April 27, 2026. The document is focused on compliance with regulatory requirements concerning related party transactions and fund occupation, and it is not a full annual report or audit report by itself but a specialized disclosure related to audit findings and regulatory guidelines. The document length is 3990 characters, which is relatively short and contains a specific explanation and summary table rather than comprehensive financial statements or full audit opinions. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone audit-related disclosure focusing on specific audit findings and regulatory compliance related to funds occupied by related parties, rather than a full annual report or other types of filings.
2026-04-28 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2025年度募集资金存放、管理与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited (the sponsor) regarding the 2025 annual special inspection opinion on the deposit, management, and use of raised funds by Chengdu Lead Drug Development Co., Ltd. It includes specifics on the amount of funds raised, usage during the year, management systems, bank accounts, investment projects, and compliance with regulatory rules. It also contains an auditor's opinion from Deloitte Hua Yong CPA and the sponsor's conclusion on the compliance of fund usage. The document is over 6,700 characters and contains substantive financial data and analysis related to the use of raised funds for the fiscal year 2025. This matches the characteristics of an Audit Report / Information (AR) type filing, which includes standalone audit reports and verification of fund usage, rather than a full Annual Report or a simple announcement. Therefore, the correct classification is AR with high confidence.
2026-04-28 Chinese
德勤华永会计师事务所(特殊普通合伙)关于成都先导药物开发股份有限公司财务报表及审计报告
Audit Report / Information Classification · 100% confidence The document is titled "财务报表及审计报告" (Financial Statements and Audit Report) for the fiscal year ending December 31, 2025. It includes detailed financial statements such as consolidated and company balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The document also contains a comprehensive audit report by Deloitte, including audit opinions, key audit matters, and auditor responsibilities. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of detailed financial data and the audit report confirms this is a standalone audit report and financial statements document, not an annual report or a simple announcement. Therefore, the appropriate classification is Audit Report / Information (AR).
2026-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.